Projekt

SAKK 17/18 Origin

Automatisch geschlossen · 2021 bis 2024

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Automatisch geschlossen
Start
2021
Ende
2024
Finanzierungsart
SAKK
Studiendesign
Phase II
Schlagwörter (Tags)
Immunotherapy combining Gemcitabine with atezolizumab, advanced NSCLC, mesothelioma progressing, immune-checkpoint inhibitors or gemcitabine
Label
Lungenkrebs
Kurzbeschreibung/Zielsetzung

A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro studies have demon-strated a synergism of immunotherapy with PD(L)1- targeting monoclonal antibodies and gemcitabine ad-ministered in different tumors models and ongoing clin-ical studies showed encouraging results. This may represent a safe and effective therapy for patients who relapsed or did not respond to standard therapies.